Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.
Identifieur interne : 000269 ( PubMed/Curation ); précédent : 000268; suivant : 000270Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.
Auteurs : F. Pieruccini-Faria [Canada] ; J A Jones [Canada] ; Q J Almeida [Canada]Source :
- Neuroscience [ 1873-7544 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Biomechanical Phenomena (drug effects), Cognition (drug effects), Dopamine (metabolism), Dopamine Agents (pharmacology), Female, Gait (drug effects), Gait Disorders, Neurologic (drug therapy), Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Psychomotor Performance (physiology), Walking (physiology).
- MESH :
- chemical , metabolism : Dopamine.
- drug effects : Biomechanical Phenomena, Cognition, Gait.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- chemical , pharmacology : Dopamine Agents.
- physiology : Psychomotor Performance, Walking.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Cognitive and sensorimotor processes are both needed for successful planning of footsteps during complex gait situations, but the interaction between these factors during motor planning, as well as their response to dopaminergic treatment is poorly understood in Parkinson's disease (PD). In the current study, we evaluated walking and gaze behaviors of individuals with PD while planning an approach toward an obstacle to be stepped over. The obstacle clearance task was completed both ON and OFF dopaminergic medication by individuals with Parkinson's disease (n=20) and compared to healthy age-matched control participants (n=19), as well as with and without an auditory digit monitoring dual task. In this novel protocol of synchronized gaze and gait data collection, each trial was split into an early and late phase prior to the obstacle, providing a unique opportunity to examine dopamine-dependent planning deficits in PD. Interestingly, only patients in the OFF medication state showed greater deceleration in the late phase (i.e., just before the obstacle) (F(1,37)=45.42, p<0.001), as well as an increase in step time variability (also in this late phase) with the additional demands of a dual task (F(2,74)=3.49, p=0.035). Only gait deceleration between approaching phases improved with dopaminergic treatment (F(1,18)=59.20; p<0.001). Although groups showed different walking behaviors, gaze behaviors were the same for all participants, in that they planned for the obstacle more so in the early phase (p<0.05), and fixations were reduced across participants with the presence of the dual task (p<0.001). Surprisingly, the gaze behavior of the PD OFF group showed no interactions with phase or condition suggesting that the deceleration and increased variability when approaching an obstacle is the result of a greater demand for online sensory feedback that cannot be compensated for with visual strategies. We conclude that dopamine influences planning by limiting sensorimotor processing capacity, especially in the presence of increased cognitive demand in PD.
DOI: 10.1016/j.neuroscience.2016.01.019
PubMed: 26794593
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000269
Links to Exploration step
pubmed:26794593Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.</title><author><name sortKey="Pieruccini Faria, F" sort="Pieruccini Faria, F" uniqKey="Pieruccini Faria F" first="F" last="Pieruccini-Faria">F. Pieruccini-Faria</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author><author><name sortKey="Jones, J A" sort="Jones, J A" uniqKey="Jones J" first="J A" last="Jones">J A Jones</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Laurier Centre for Cognitive Neuroscience, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Laurier Centre for Cognitive Neuroscience, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author><author><name sortKey="Almeida, Q J" sort="Almeida, Q J" uniqKey="Almeida Q" first="Q J" last="Almeida">Q J Almeida</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada. Electronic address: qalmeida@wlu.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26794593</idno><idno type="pmid">26794593</idno><idno type="doi">10.1016/j.neuroscience.2016.01.019</idno><idno type="wicri:Area/PubMed/Corpus">000269</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000269</idno><idno type="wicri:Area/PubMed/Curation">000269</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000269</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.</title><author><name sortKey="Pieruccini Faria, F" sort="Pieruccini Faria, F" uniqKey="Pieruccini Faria F" first="F" last="Pieruccini-Faria">F. Pieruccini-Faria</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author><author><name sortKey="Jones, J A" sort="Jones, J A" uniqKey="Jones J" first="J A" last="Jones">J A Jones</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Laurier Centre for Cognitive Neuroscience, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Laurier Centre for Cognitive Neuroscience, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author><author><name sortKey="Almeida, Q J" sort="Almeida, Q J" uniqKey="Almeida Q" first="Q J" last="Almeida">Q J Almeida</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada. Electronic address: qalmeida@wlu.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5</wicri:regionArea></affiliation></author></analytic><series><title level="j">Neuroscience</title><idno type="eISSN">1873-7544</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Biomechanical Phenomena (drug effects)</term><term>Cognition (drug effects)</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (pharmacology)</term><term>Female</term><term>Gait (drug effects)</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Psychomotor Performance (physiology)</term><term>Walking (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Biomechanical Phenomena</term><term>Cognition</term><term>Gait</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term><term>Walking</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive and sensorimotor processes are both needed for successful planning of footsteps during complex gait situations, but the interaction between these factors during motor planning, as well as their response to dopaminergic treatment is poorly understood in Parkinson's disease (PD). In the current study, we evaluated walking and gaze behaviors of individuals with PD while planning an approach toward an obstacle to be stepped over. The obstacle clearance task was completed both ON and OFF dopaminergic medication by individuals with Parkinson's disease (n=20) and compared to healthy age-matched control participants (n=19), as well as with and without an auditory digit monitoring dual task. In this novel protocol of synchronized gaze and gait data collection, each trial was split into an early and late phase prior to the obstacle, providing a unique opportunity to examine dopamine-dependent planning deficits in PD. Interestingly, only patients in the OFF medication state showed greater deceleration in the late phase (i.e., just before the obstacle) (F(1,37)=45.42, p<0.001), as well as an increase in step time variability (also in this late phase) with the additional demands of a dual task (F(2,74)=3.49, p=0.035). Only gait deceleration between approaching phases improved with dopaminergic treatment (F(1,18)=59.20; p<0.001). Although groups showed different walking behaviors, gaze behaviors were the same for all participants, in that they planned for the obstacle more so in the early phase (p<0.05), and fixations were reduced across participants with the presence of the dual task (p<0.001). Surprisingly, the gaze behavior of the PD OFF group showed no interactions with phase or condition suggesting that the deceleration and increased variability when approaching an obstacle is the result of a greater demand for online sensory feedback that cannot be compensated for with visual strategies. We conclude that dopamine influences planning by limiting sensorimotor processing capacity, especially in the presence of increased cognitive demand in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26794593</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>13</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7544</ISSN><JournalIssue CitedMedium="Internet"><Volume>318</Volume><PubDate><Year>2016</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>Neuroscience</Title><ISOAbbreviation>Neuroscience</ISOAbbreviation></Journal><ArticleTitle>Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.</ArticleTitle><Pagination><MedlinePgn>219-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroscience.2016.01.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0306-4522(16)00038-5</ELocationID><Abstract><AbstractText>Cognitive and sensorimotor processes are both needed for successful planning of footsteps during complex gait situations, but the interaction between these factors during motor planning, as well as their response to dopaminergic treatment is poorly understood in Parkinson's disease (PD). In the current study, we evaluated walking and gaze behaviors of individuals with PD while planning an approach toward an obstacle to be stepped over. The obstacle clearance task was completed both ON and OFF dopaminergic medication by individuals with Parkinson's disease (n=20) and compared to healthy age-matched control participants (n=19), as well as with and without an auditory digit monitoring dual task. In this novel protocol of synchronized gaze and gait data collection, each trial was split into an early and late phase prior to the obstacle, providing a unique opportunity to examine dopamine-dependent planning deficits in PD. Interestingly, only patients in the OFF medication state showed greater deceleration in the late phase (i.e., just before the obstacle) (F(1,37)=45.42, p<0.001), as well as an increase in step time variability (also in this late phase) with the additional demands of a dual task (F(2,74)=3.49, p=0.035). Only gait deceleration between approaching phases improved with dopaminergic treatment (F(1,18)=59.20; p<0.001). Although groups showed different walking behaviors, gaze behaviors were the same for all participants, in that they planned for the obstacle more so in the early phase (p<0.05), and fixations were reduced across participants with the presence of the dual task (p<0.001). Surprisingly, the gaze behavior of the PD OFF group showed no interactions with phase or condition suggesting that the deceleration and increased variability when approaching an obstacle is the result of a greater demand for online sensory feedback that cannot be compensated for with visual strategies. We conclude that dopamine influences planning by limiting sensorimotor processing capacity, especially in the presence of increased cognitive demand in PD.</AbstractText><CopyrightInformation>Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pieruccini-Faria</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Psychology Department, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada; Laurier Centre for Cognitive Neuroscience, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Q J</ForeName><Initials>QJ</Initials><AffiliationInfo><Affiliation>Sun Life Financial Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada. Electronic address: qalmeida@wlu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroscience</MedlineTA><NlmUniqueID>7605074</NlmUniqueID><ISSNLinking>0306-4522</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">dopaminergic system</Keyword><Keyword MajorTopicYN="N">eye tracking</Keyword><Keyword MajorTopicYN="N">gait control</Keyword><Keyword MajorTopicYN="N">motor planning</Keyword><Keyword MajorTopicYN="N">obstacle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26794593</ArticleId><ArticleId IdType="pii">S0306-4522(16)00038-5</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2016.01.019</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000269 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000269 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26794593
|texte= Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26794593" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |